Business Segment Information

12 Months Ended

Dec. 31, 2012

Business Segments

Business Segment Information [Text Block]

Note 3.Business Segment and Geographical Information

       The company's continuing operations fall into three business segments as follows:

       Analytical Technologies: provides a broad offering ofinstruments, reagents, consumables, software and services that are used for a range of applications in the laboratory, on the production line and in the field. These products and services are used by customers in pharmaceutical, biotechnology, academic, government and other research and industrial markets, as well as the clinical laboratory.

       Specialty Diagnostics: provides a wide range of diagnostic test kits, reagents, culture media, instruments and associated products used to increase the speed and accuracy of diagnoses. These products are used primarily by customers in healthcare, clinical, pharmaceutical, industrial and food safety laboratories.

       Laboratory Products and Services: provides virtually everything needed for the laboratory,including a combination of self-manufactured and sourced products and an extensive service offering. These products and services are used by customers in pharmaceutical, biotechnology, academic, government and other research and industrial markets, as well as the clinical laboratory.

In February 2013, in connection with a change in management responsibility for two product lines, the company transferred its water analysis and research serum media product lines to the Laboratory Products and Services segment from the Analytical Technologies segment. The company has historically moved a product line between segments when a shift in strategic focus of either the product line or a segment more closely aligns the product line with a segment different than that in which it had previously been reported. Prior period segment information has been reclassified to reflect these transfers.

       The company's management evaluates segment operating performance based on operating income before certain charges/credits to cost of revenues and selling, general and administrative expenses, principally associated with acquisition accounting; restructuring and other costs/income including costs arising from facility consolidations such as severance and abandoned lease expense and gains and losses from the sale of real estate and product lines; and amortization of acquisition-related intangible assets. The company uses this measure because it helps management understand and evaluate the segments' core operating results and facilitates comparison of performance for determining compensation.

Business Segment Information

(In millions)			2012		2011		2010
Revenues
	Analytical Technologies		$	4,017.9	$	3,739.7	$	3,137.1
	Specialty Diagnostics			2,962.3		2,469.9		2,149.0
	Laboratory Products and Services			6,053.7		5,831.2		5,539.8
	Eliminations			(524.0)		(482.0)		(432.8)
		Consolidated revenues		12,509.9		11,558.8		10,393.1
Segment Income
	Analytical Technologies (a)			749.1		694.8		525.0
	Specialty Diagnostics (a)			761.2		598.4		487.9
	Laboratory Products and Services (a)			869.6		836.1		806.3
		Subtotal reportable segments (a)		2,379.9		2,129.3		1,819.2
	Cost of revenues charges			(55.6)		(72.6)		(13.2)
	Selling, general and administrative charges, net			(12.5)		(61.5)		(3.0)
	Restructuring and other costs, net			(82.1)		(96.5)		(60.2)
	Amortization of acquisition-related intangible assets			(747.6)		(647.9)		(554.7)
		Consolidated operating income		1,482.1		1,250.8		1,188.1
	Other expense, net (b)			(212.7)		(118.0)		(100.4)
	Income from continuing operations before income taxes		$	1,269.4	$	1,132.8	$	1,087.7
Depreciation
	Analytical Technologies		$	64.0	$	59.9	$	53.9
	Specialty Diagnostics			73.0		50.1		37.3
	Laboratory Products and Services			99.1		101.7		93.8
		Consolidated depreciation	$	236.1	$	211.7	$	185.0
(a)	Represents operating income before certain charges to cost of revenues and selling, general and administrative expenses; restructuring and other costs, net; and amortization of acquisition-related intangibles.
(b)	The company does not allocate other expense, net to its segments.

(In millions)			2012		2011		2010
Total Assets
	Analytical Technologies		$	5,676.2	$	6,085.0	$	4,100.6
	Specialty Diagnostics			9,841.0		8,319.6		4,575.9
	Laboratory Products and Services			11,275.8		10,891.7		10,933.9
	Corporate/Other (c)			651.6		1,537.4		1,739.0
		Consolidated total assets	$	27,444.6	$	26,833.7	$	21,349.4
Capital Expenditures
	Analytical Technologies		$	75.1	$	69.5	$	43.2
	Specialty Diagnostics			97.6		63.2		51.0
	Laboratory Products and Services			106.4		115.7		125.8
	Corporate/Other			36.0		12.5		25.4
		Consolidated capital expenditures	$	315.1	$	260.9	$	245.4
(c)	Corporate assets consist primarily of cash and cash equivalents, short-term investments, property and equipment at the company's corporate offices and assets of the discontinued operations.
Geographical Information
(In millions)			2012		2011		2010
Revenues (d)
	United States		$	6,424.4	$	6,023.9	$	5,806.8
	China			735.8		559.6		405.3
	Germany			681.5		698.3		592.9
	United Kingdom			507.1		472.3		409.6
	Other			4,161.1		3,804.7		3,178.5
			$	12,509.9	$	11,558.8	$	10,393.1
Long-lived Assets (e)
	United States		$	862.4	$	797.9	$	708.5
	United Kingdom			223.9		209.2		170.4
	Germany			165.2		158.6		121.7
	Other			474.9		445.6		319.3
			$	1,726.4	$	1,611.3	$	1,319.9
(d)	Revenues are attributed to countries based on customer location.
(e)	Includes property, plant and equipment, net.